Inhibikase Therapeutics (IKT) Cash from Financing Activities (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Cash from Financing Activities data on file, last reported at $2.9 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities changed N/A year-over-year to $2.9 million in Q1 2026; TTM through Mar 2026 was $111.4 million, a 8.0% increase from a year earlier, with the FY2025 full-year figure at $108.5 million, up 4.82% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $2.9 million, down from $108.6 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for IKT reached as high as $108.6 million in Q4 2025 and fell as low as -$204769.0 in Q1 2022.
• Historically, Cash from Financing Activities has averaged $17.2 million across 5 years, with a median of $181954.0 in 2024.
• Across the five-year window, Cash from Financing Activities soared 259834.29% in 2024 and plunged 173.72% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at -$204769.0 in 2022, then jumped by 32.56% to -$138104.0 in 2023, then surged by 72280.72% to $99.7 million in 2024, then climbed by 8.91% to $108.6 million in 2025, then tumbled by 97.33% to $2.9 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $2.9 million in Q1 2026, $108.6 million in Q4 2025, and -$134130.0 in Q3 2025.